Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia

Abstract

We report the discovery of GATA2 as a new myelodysplastic syndrome (MDS)-acute myeloid leukemia (AML) predisposition gene. We found the same, previously unidentified heterozygous c.1061C>T (p.Thr354Met) missense mutation in the GATA2 transcription factor gene segregating with the multigenerational transmission of MDS-AML in three families and a GATA2 c.1063_1065delACA (p.Thr355del) mutation at an adjacent codon in a fourth MDS family. The resulting alterations reside within the second zinc finger of GATA2, which mediates DNA-binding and protein-protein interactions. We show differential effects of the mutations on the transactivation of target genes, cellular differentiation, apoptosis and global gene expression. Identification of such predisposing genes to familial forms of MDS and AML is critical for more effective diagnosis and prognosis, counseling, selection of related bone marrow transplant donors and development of therapies.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Identification of new germline p.Thr354Met and p.Thr355del variants in the highly conserved zinc finger 2 domain of GATA2 that is associated with MDS-AML.
Figure 2: Subcellular localization and DNA binding properties of wild-type and mutant GATA2.
Figure 3: p.Thr354Met and Thr355del cause altered transactivation through target GATA2 response elements.
Figure 4: p.Thr354Met inhibits differentiation and apoptosis while allowing accumulation of cells in the presence of ATRA-induced differentiation.

Accession codes

Accessions

Gene Expression Omnibus

NCBI Reference Sequence

References

  1. 1

    Vardiman, J.W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937–951 (2009).

  2. 2

    Barzi, A. & Sekeres, M.A. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve. Clin. J. Med. 77, 37–44 (2010).

  3. 3

    Owen, C., Barnett, M. & Fitzgibbon, J. Familial myelodysplasia and acute myeloid leukaemia–a review. Br. J. Haematol. 140, 123–132 (2008).

  4. 4

    Zhang, P. et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc. Natl. Acad. Sci. USA 96, 8705–8710 (1999).

  5. 5

    Crossley, M., Merika, M. & Orkin, S.H. Self-association of the erythroid transcription factor GATA-1 mediated by its zinc finger domains. Mol. Cell. Biol. 15, 2448–2456 (1995).

  6. 6

    Zhang, S.J. et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 105, 2076–2081 (2008).

  7. 7

    Yan, X.J. et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat. Genet. 43, 309–315 (2011).

  8. 8

    Usary, J. et al. Mutation of GATA3 in human breast tumors. Oncogene 23, 7669–7678 (2004).

  9. 9

    Owen, C.J. et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 112, 4639–4645 (2008).

  10. 10

    Carmichael, C.L. et al. Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes. Br. J. Haematol. 150, 382–385 (2010).

  11. 11

    Robinson, C.W., Norman, J.E., Cleland, L.G. & Ford, J.H. Dermal necrosis and chromosome Iq abnormality in a man with a familial myeloproliferative disorder. Aust. N. Z. J. Med. 13, 141–145 (1983).

  12. 12

    Horwitz, M., Sabath, D.E., Smithson, W.A. & Radich, J. A family inheriting different subtypes of acute myelogenous leukemia. Am. J. Hematol. 52, 295–304 (1996).

  13. 13

    Minelli, A. et al. Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene. Cancer Genet. Cytogenet. 124, 147–151 (2001).

  14. 14

    Michaud, J. et al. Integrative analysis of RUNX1 downstream pathways and target genes. BMC Genomics 9, 363 (2008).

  15. 15

    Veitia, R.A. Dominant negative factors in health and disease. J. Pathol. 218, 409–418 (2009).

  16. 16

    Ernst, T. et al. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 95, 1473–1480 (2010).

  17. 17

    Matheny, C.J. et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J. 26, 1163–1175 (2007).

  18. 18

    Kitajima, K. et al. Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2. Blood 107, 1857–1863 (2006).

  19. 19

    Tsai, F.Y. et al. An early haematopoietic defect in mice lacking the transcription factor GATA-2. Nature 371, 221–226 (1994).

  20. 20

    Zhang, S.J. & Shi, J.Y. GATA-2 L359V mutation is solely associated with CML progression but not other hematological malignancies. Blood 112, Abstract 1507 (2008).

  21. 21

    Zhang, S.J., Shi, J.Y. & Li, J.Y. GATA-2 L359V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism. Leuk. Res. 33, 1141–1143 (2009).

  22. 22

    Fadilah, S.A., Cheong, S.K., Roslan, H., Rozie-Hanisa, M. & Yen, G.K. GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome. Leukemia 16, 1563–1565 (2002).

  23. 23

    Bullinger, L. et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 24, 438–449 (2010).

  24. 24

    Wieser, R. et al. Transcription factor GATA-2 gene is located near 3q21 breakpoints in myeloid leukemia. Biochem. Biophys. Res. Commun. 273, 239–245 (2000).

  25. 25

    Bullinger, L. et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605–1616 (2004).

  26. 26

    Lahortiga, I. et al. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements. Genes Chromosom. Cancer 40, 179–189 (2004).

  27. 27

    Slape, C. et al. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation. Cancer Res. 67, 5148–5155 (2007).

  28. 28

    Hsu, A.P. et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood published online, doi:10.1182/blood-2011-05-356352 (13 June 2011).

  29. 29

    Dickinson, R.E. et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood published online, doi:10.1182/blood-2011-06-360313 (15 July 2011).

  30. 30

    Mansour, S. et al. Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases. Am. J. Med. Genet. A 152A, 2287–2296 (2010).

  31. 31

    Ostergaard, P. et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat. Genet. advance online publication, doi:10.1038/ng.923 (4 September 2011).

  32. 32

    Tsuzuki, S., Towatari, M., Saito, H. & Enver, T. Potentiation of GATA-2 activity through interactions with the promyelocytic leukemia protein (PML) and the t(15;17)-generated PML-retinoic acid receptor alpha oncoprotein. Mol. Cell. Biol. 20, 6276–6286 (2000).

  33. 33

    Diessenbacher, P. et al. NF-κB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J. Invest. Dermatol. 128, 1134–1147 (2008).

  34. 34

    Callus, B.A. et al. Triggering of apoptosis by Puma is determined by the threshold set by prosurvival Bcl-2 family proteins. J. Mol. Biol. 384, 313–323 (2008).

  35. 35

    Koldej, R., Cmielewski, P., Stocker, A., Parsons, D.W. & Anson, D.S. Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production. J. Gene Med. 7, 1390–1399 (2005).

  36. 36

    Kumar, R. et al. CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene HEB. J. Biol. Chem. 283, 19026–19038 (2008).

Download references

Acknowledgements

The authors would like to thank the families for their participation in our studies. Thanks also to J. Melo for provision of CML cell lines and R. Sharma for help with EMSA. Large-scale Sanger sequencing was performed by the Australian Genome Research Facility, which was established through the Commonwealth-funded Major National Research Facilities program. This work was supported by grants from the National Health and Medical Research Council of Australia (program grants 257501 (H.S.S.) and 219176 (H.S.S.), project grant 1002317 (C.N.H., R.J.D. and H.S.S.), fellowships 171601 (H.S.S.) and 461204 (H.S.S.), and a Dora Lush Postgraduate Award (C.L.C.)), Leukaemia Foundation of Australia (grant in aid to H.S.S. and a postdoctoral fellowship to C.L.C.), the Cancer Council of South Australia (H.S.S.) and MedVet Pty Ltd (H.S.S. and R.J.D.), Adelaide Scholarships International (scholarship to C.-E.C.) and US National Institutes of Health grant R01DK058161 (M.S.H.).

Author information

C.N.H., R.J.D., M.S.H. and H.S.S. managed the project. C.N.H., C.L.C., E.J.W., C.-E.C., P.J.B., X.-C.L., M.B., M.L., A.C., Y.K.L., C.M.B., K.L.F. and A.E.T. performed the experiments. C.H.K. and R.J.D. performed structural modeling, and C.N.H., C.H.K. and L.G. performed data analysis. L.B.T., M.A., J.S., P.G.B., G.K.S., R.J.D., M.S.H. and H.S.S. collected families with MDS and/or AML and provided clinical data and samples. R.E. and P.G.E. participated in experimental design and provided critical reagents. A.L.B., I.D.L., S.M. and L.B.T. provided sporadic AML samples and correlative clinical data. C.N.H., R.J.D., M.S.H. and H.S.S. wrote the manuscript.

Correspondence to Hamish S Scott.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–8, Supplementary Tables 1–13 and Supplementary Note. (PDF 1327 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hahn, C., Chong, C., Carmichael, C. et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 43, 1012–1017 (2011). https://doi.org/10.1038/ng.913

Download citation

Further reading